Table 3 Subgroup analyses of the effects of cell therapy on secondary lymphedema
From: Cell therapy as a treatment of secondary lymphedema: a systematic review and meta-analysis
Subgroup | Experiments (N) | Hedges' G (SMD) | SEg | 95%CI-Lower | 95%CI-Upper | z score | p value | Heterogeneity % |
|---|---|---|---|---|---|---|---|---|
(1) Edema | ||||||||
 All studies | 11 | 3.183 | 0.706 | 1.798 | 4.567 | 4.506 | 0.000 | 92.250 |
 Animal model |  |  |  |  |  |  |  |  |
  Tail model | 5 | 3.330 | 0.963 | 1.442 | 5.217 | 3.458 | 0.001 | 88.307 |
  Hindlimb model | 5 | 3.329 | 1.315 | 0.751 | 5.907 | 2.531 | 0.011 | 95.132 |
 Cell type | ||||||||
  Stem or progenitor cells (BM-MSC, ADSC, MAPC) | 9 | 3.282 | 0.831 | 1.652 | 4.911 | 3.948 | 0.000 | 92.932 |
  Differentiated cells (LEC, Treg) | 2 | 3.197 | 0.438 | 2.339 | 4.055 | 7.305 | 0.000 | 0.989 |
(2) Lymphatic vessels | ||||||||
 All studies | 10 | 6.348 | 1.139 | 4.115 | 8.581 | 5.571 | 0.000 | 92.650 |
 Animal model |  |  |  |  |  |  |  |  |
  Tail model | 4 | 6.661 | 2.157 | 2.434 | 10.889 | 3.089 | 0.002 | 95.592 |
  Hindlimb model | 5 | 5.736 | 1.243 | 3.299 | 8.173 | 4.613 | 0.000 | 84.502 |